These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 33602684)
1. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684 [TBL] [Abstract][Full Text] [Related]
2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645 [TBL] [Abstract][Full Text] [Related]
3. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983 [TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. DeAngelo DJ; Advani AS; Marks DI; Stelljes M; Liedtke M; Stock W; Gökbuget N; Jabbour E; Merchant A; Wang T; Vandendries E; Neuhof A; Kantarjian H; O'Brien S Blood Cancer J; 2020 Aug; 10(8):81. PubMed ID: 32769965 [TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Li X; Zhou M; Qi J; Han Y Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e227-e247. PubMed ID: 33461955 [TBL] [Abstract][Full Text] [Related]
8. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Cassaday RD; Marks DI; DeAngelo DJ; Jabbour EJ; Advani AS; O'Brien S; Wang T; Neuhof A; Vandendries E; Kantarjian HM; Stock W; Stelljes M Br J Haematol; 2020 Nov; 191(3):e77-e81. PubMed ID: 32805058 [No Abstract] [Full Text] [Related]
9. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420 [TBL] [Abstract][Full Text] [Related]
10. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745 [TBL] [Abstract][Full Text] [Related]
11. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984 [TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Jabbour E; Advani AS; Stelljes M; Stock W; Liedtke M; Gökbuget N; Martinelli G; O'Brien S; White JL; Wang T; Luisa Paccagnella M; Sleight B; Vandendries E; DeAngelo DJ; Kantarjian HM Am J Hematol; 2019 Apr; 94(4):408-416. PubMed ID: 30623490 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Chen J; Haughey M; Vandendries E; DeAngelo DJ; Kantarjian HM; Ruiz-Garcia A Clin Transl Sci; 2021 Jan; 14(1):184-193. PubMed ID: 32812370 [TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia. Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837 [No Abstract] [Full Text] [Related]
15. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Wynne J; Wright D; Stock W Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147 [TBL] [Abstract][Full Text] [Related]
16. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Zhao Y; Laird AD; Roberts KG; Yafawi R; Kantarjian H; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien S; Jabbour E; Cassaday RD; Loyd MR; Olsen S; Neale G; Liu X; Vandendries E; Advani A; Mullighan CG Blood Adv; 2024 Jun; 8(12):3226-3236. PubMed ID: 38607410 [TBL] [Abstract][Full Text] [Related]
17. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056 [TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system. Lee TY; Chen HY; Chen TY; Li SS; Fang WT; Wen YC; Lo YW; Ou HT Eur J Health Econ; 2020 Sep; 21(7):1105-1116. PubMed ID: 32506280 [TBL] [Abstract][Full Text] [Related]